0211 Ensoma
BioCentury & Getty Images

Emerging Company Profile

With $70M A round, Takeda deal, 5AM’s Ensoma aims for accessible cell and gene therapies via empty adenoviral vectors

Emerging Company Profile: Ensoma is taking on ex vivo HSC therapies

5AM’s Kush Parmar’s latest venture is taking on ex vivo HSC therapies with a $70 million series A round and a deal with Takeda.

Feb 12, 2021 | 3:04 AM GMT

Launched with a $70 million series A round and a Takeda deal in hand, Ensoma is the latest company focused on broadening access to cell and gene therapies, leveraging high-capacity vectors to  develop one-time, off-the-shelf treatments.

Ensoma is betting its genome-free adenoviral vectors, which can

Read the full 1103 word article

How to gain access

Continue reading with a
two-week free trial.